Maintenance of NOD/SL-IC Numbers In Vivo
| Patient . | No.NOD/SL-IC per 1° Mouse Day 0 . | % BM From 1° Mouse Injected per 2° Mouse5-150 . | No.Positive 2° Mice . | % CD45+ Cells in Positive 2° Mice . | Estimated No. NOD/SL-IC in 1° Mouse at Week 3-45-151 . |
|---|---|---|---|---|---|
| 5 | 21 | 5 | 2/3 | 1.9, 2.6 | 20 |
| 9 | 5 | 5 | 1/3 | 1.2 | 10 |
| 10 | 45 | 10 | 2/3 | 1.8, 3.0 | 10 |
| Patient . | No.NOD/SL-IC per 1° Mouse Day 0 . | % BM From 1° Mouse Injected per 2° Mouse5-150 . | No.Positive 2° Mice . | % CD45+ Cells in Positive 2° Mice . | Estimated No. NOD/SL-IC in 1° Mouse at Week 3-45-151 . |
|---|---|---|---|---|---|
| 5 | 21 | 5 | 2/3 | 1.9, 2.6 | 20 |
| 9 | 5 | 5 | 1/3 | 1.2 | 10 |
| 10 | 45 | 10 | 2/3 | 1.8, 3.0 | 10 |
1° mice were killed 3 to 4 weeks postinjection of AML cells. Marrow harvested from these animals was injected into secondary recipients that were killed for analysis 8 weeks later.
Using Poisson statistics it was estimated that when 2/3 of 2° mice showed engraftment with human cells on average 1 NOD/SL-IC was present in the fraction of 1° mouse marrow initially injected into 2° recipients.